DLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity

Molecular and Cellular Biology

Volumn 32, Issue 11, 2012, Pages 2145-2159

  Tripathi, Veenu ^a   Popescu, Nicholas C ^a   Zimonjic, Azen B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ALPHA CATENIN; BETA CATENIN; FOR DELETED IN LIVER CANCER 1 PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL JUNCTION; CELL MEMBRANE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOSOL; EMBRYO; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS INHIBITION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

ADHERENS JUNCTIONS; ALPHA CATENIN; BINDING SITES; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; GTPASE-ACTIVATING PROTEINS; HUMANS; MALE; NEOPLASM METASTASIS; PROTEIN BINDING; RHO GTP-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84864008196     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06580-11     Document Type: Article

References (70)

1. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Kosma VM. 1999. Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer. Br. J. Cancer 80:477-482.
2. Arbieva ZH, et al. 2000. High-resolution physical map and transcript identification of a prostate cancer deletion interval on 8p22. Genome Res. 10:244-257.
3. Ayollo DV, Zhitnyak IY, Vasiliev JM, Gloushankova NA. 2009. Rearrangements of the actin cytoskeleton and E-cadherin-based adherens junctions caused by neoplasic transformation change cell-cell interactions. PLoS One 30:e8027.
4. Baloch ZW, Pasha T, LiVolsi VA. 2001. Cytoplasmic accumulation of alpha-catenin in thyroid neoplasms. Head Neck 23:573-578.
5. Berx G, Van Roy F. 2001. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 3:289-293.
6. Bishop JM. 1987. The molecular genetics of cancer. Science 235:305-311.
7. Bullions LC, Notterman DA, Chung LS, Levine AJ. 1997. Expression of wild-type alpha-catenin protein in cells with a mutant alpha-catenin gene restores both growth regulation and tumor suppressor activities. Mol. Cell. Biol. 17:4501-4508.
8. Cavey M, Rauzi M, Lenne PF, Lecuit T. 2008. A two-tiered mechanism for stabilization and immobilization of E-cadherin. Nature 453:751-756.
9. Cheng I, et al. 2012. Copy number alterations in prostate tumors and disease aggressiveness. Genes Chromosomes Cancer 51:66-76.
10. Czyzewska J, Guzińska-Ustymowicz K, Ustymowicz MM, Pryczynicz A, Kemona A. 2010. The expression of E-cadherin-catenin complex in patients with advanced gastric cancer: role in formation of metastasis. Folia Histochem. Cytobiol. 48:37-45.
11. Ding L, et al. 2010. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999-1005.
12. Drees F, Pokutta S, Yamada S, Nelson WJ, Weis WI. 2005. Alphacatenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell 123:903-915.
13. Durkin ME, et al. 2007. DLC-1: a Rho GTPase-activating protein and tumour suppressor. J. Cell. Mol. Med. 11:1185-1207.
14. Durkin ME, et al. 2005. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett. 579:1191-1196.
15. Giehl K, Menke A. 2008. Microenvironmental regulation of E-cadherinmediated adherens junctions. Front. Biosci. 13:3975-3985.
16. Goodison S, et al. 2005. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 65:6042-6053.
17. Guan M, Tripathi V, Zhou X, Popescu NC. 2008. Adenovirus-mediated restoration of expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines: prospects for gene therapy. Cancer Gene Ther. 15:371-381.
18. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC. 2006. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin. Cancer Res. 12:1412-1419.
19. Hall A. 2009. The cytoskeleton and cancer. Cancer Metastasis Rev. 28:5-14.
20. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
21. Healy KD, et al. 2008. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol. Carcinog. 47:326-337.
22. Hirohashi S. 1998. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am. J. Pathol. 153:333-339.
23. Hirvikoski P, et al. 1998. Cytoplasmic accumulation of alpha-catenin is associated with aggressive features in laryngeal squamous-cell carcinoma. Int. J. Cancer 79:546-550.
24. Huber O, Krohn M, Kemler R. 1997. A specific domain in alpha-catenin mediates binding to beta-catenin or plakoglobin. J. Cell Sci. 110:1759-1765.
25. Kadowaki T, et al. 1994. E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res. 54:291-296.
26. Kim TY, Vigil D, Der CJ, Juliano RL. 2009. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev. 28:77-83.
27. Kim TY, et al. 2008. Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration. J. Biol. Chem. 283:32762-32770.
28. Ko FC, et al. 2010. Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology 139:1397-1407.
29. Lahoz A, Hall A. 2008. DLC1: a significant GAP in the cancer genome. Genes Dev. 22:1724-1730.
30. Liao YC, Lo SH. 2008. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int. J. Biochem. Cell Biol. 40:843-847.
31. Liao Y-C, Si L, DeVere White RW, Lo SH. 2007. The phosphotyrosineindependent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J. Cell Biol. 176:43-49.
32. Macoska JA, et al. 1995. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res. 55:5390-5395.
33. Matsuyama H, et al. 2001. Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer. Clin. Cancer Res. 7:3139-3143.
34. Moon RT, Bowerman B, Boutros M, Perrimon N. 2002. The promise and perils of Wnt signaling through beta-catenin. Science 296:1644-1646.
35. Nakopoulou L, et al. 2002. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 40:536-546.
36. Pirinen RT, Hirvikoski P, Johansson RT, Hollmén S, Kosma VM. 2001. Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J. Clin. Pathol. 54:391-395.
37. Plumb CL, et al. 2009. Modulation of the tumor suppressor protein alpha-catenin by ischemic microenvironment. Am. J. Pathol. 175:1662-1674.
38. Pryczynicz A, Guzińska-Ustymowicz K, Kemona A, Czyzewska J. 2010. Expression of the E-cadherin-catenin complex in patients with pancreatic ductal adenocarcinoma. Folia Histochem. Cytobiol. 48:128-133.
39. Qian X, et al. 2007. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPaseactivating protein activities. Proc. Natl. Acad. Sci. U. S. A. 104:9012-9017.
40. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. 1997. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 57:3189-3193.
41. Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. 1995. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc. Natl. Acad. Sci. U. S. A. 92:8813-8817.
42. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava EM, Kosma VM. 1999. Reduced expression of alpha catenin is associated with poor prognosis in colorectal carcinoma. J. Clin. Pathol. 52:10-16.
43. Sahai E, Marshall CJ. 2002. RHO-GTPases and cancer. Nat. Rev. Cancer 2:133-142.
44. Sahai E, Marshall CJ. 2002. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat. Cell Biol. 4:408-415.
45. Scholz RP, et al. 2009. DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. J. Cell Sci. 122: 92-102.
46. Serrels A, et al. 2009. Real-time study of E-cadherin and membrane dynamics in living animals: implications for disease modeling and drug development. Cancer Res. 69:2714-2719.
47. Setoyama T, et al. 2007. Alpha-catenin is a significant prognostic factor than E-cadherin in esophageal squamous cell carcinoma. J. Surg. Oncol. 95:148-155.
48. Shih YP, Yoshikazu T, Hao LS. 2012. Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells. Mol. Cancer Res. 10:34-39.
49. Shih YP, Liao YC, Lin Y, Lo SH. 2010. DLC1 negatively regulates angiogenesis in a paracrine fashion. Cancer Res. 70:8270-8275.
50. Shiozaki H, et al. 1994. Immunohistochemical detection of alpha-catenin expression in human cancers. Am. J. Pathol. 144:667-674.
51. Sousa S, et al. 2005. ARHGAP10 is necessary for alpha-catenin recruitment at adherens junctions and for Listeria invasion. Nat. Cell Biol. 7:954-960.
52. Stehbens SJ, et al. 2006. Dynamic microtubules regulate the local concentration of E-cadherin at cell-cell contacts. J. Cell Sci. 119:1801-1811.
53. Struski S, Doco-Fenzy M, Cornillet-Lefebvre P. 2002. Compilation of published comparative genomic hybridization studies. Cancer Genet. Cytogenet. 135:63-90.
54. Thiery JP. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2:442-454.
55. Ullmannova-Benson V, et al. 2009. DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia 23:383-390.
56. Vasioukhin V, Bauer C, Degenstein L, Wise B, Fuchs E. 2001. Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell 104:605-617.
57. Vermeulen SJ, et al. 1995. Transition from the noninvasive to the invasive phenotype and loss of alpha-catenin in human colon cancer cells. Cancer Res. 55:4722-4728.
58. Vigil D, Cherfils J, Rossman Kl, Der CJ. 2010. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 12:842-857.
59. Wong CM, et al. 2005. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res. 65:8861-8868.
60. Xue W, et al. 2008. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev. 22:1439-1444.
61. Yam JW, Ko FC, Chan CY, Jin DY, Ng IO. 2006. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 66:8367-8372.
62. Yang X, Popescu NC, Zimonjic DB. 2011. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Cancer Res. 71:2916-2925.
63. Yang XY, et al. 2009. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene 28:1401-1409.
64. Yuan BZ, Jefferson AM, Millecchia L, Popescu NC, Reynolds SH. 2007. Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Exp. Cell Res. 313:3868-3880.
65. Yuan BZ, et al. 2004. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 23:405-411.
66. Yuan BZ, et al. 1998. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 58:2196-2199.
67. Zhong D, et al. 2009. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J. Cell Sci. 122:414-424.
68. Zhou X, et al. 2008. DLC1 suppresses distant dissemination of humanhepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down regulation of genes involved in metastasis. Int. J. Oncol. 32:1258-1291.
69. Zhou X, Thorgeirsson SS, Popescu NC. 2004. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 23:1308-1313.
70. Zhou X, Yang X-Y, Popescu NC. 2010. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. Int. J. Oncol. 36:999-1005.